Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302 in active ankylosing spondylitis (II/III)
CTR20201491Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivarmacitinib in ankylosing spondylitis (AS), sponsored by Hengrui Therapeutics. Started Jul 2020; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20201491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201491.